Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study

• DOI: 10.1080/13696998.2023.2236867
• Publication Date: 2023-07-13T19:14:51Z
• Authors: Yen Chung; Diego J. Maselli; Fan Mu; Erin E. Cook; Danni Yang; Joshua A. Young; Keith A. Betts; Eduardo Genofre; Donna Carstens
• Keywords: Benralizumab; Asthma Exacerbations

Benralizumab is a biologic add-on treatment for severe eosinophilic asthma that can reduce the rate of exacerbations, but data on associated medical utilization are scarce. This retrospective study evaluated economic value benralizumab by analyzing healthcare resource (HRU) and costs in large patient population US.Insurance claims (11/2016-6/2020) were analyzed. A pre-post design was used to compare exacerbation rates, HRU 12 months pre vs. post index (day after initiation). Patients aged ≥12 years, with ≥2 records exacerbations index, constituted non-mutually exclusive cohorts: biologic-naïve, biologic-experienced (switched from omalizumab or mepolizumab benralizumab), extended follow-up (18 24 months).In all cohorts (mean age 51-53 years; 67-70% female; N = 1,292; biologic-experienced, 349; 18-month follow-up, 419; 24-month 156), reduced 53-68% (p < .001). In biologic-naïve cohort, inpatient admissions decreased 58%, emergency department visits 54%, outpatient 58% (all p .001), similar reductions exacerbation-related other cohorts. Exacerbation-related mean total 51% cohort ($4691 pre-index, $2289 post-index), cost differences ranging 16% 64% across (prior omalizumab: $2686 $1600; prior mepolizumab: $5990 $5008; 18-month: $3636 $1667; 24-month: $4014 $1449; Medical durable, decreasing year 1 66% 2 month cohort.Patients treated experienced regardless use, benefits observed up initiation.Benralizumab approved as an asthma. Previous real-world studies clinical trials have shown systemic corticosteroid use. However, there little information populations. showed patients United States had lower rates starting benralizumab. The also fewer hospitalizations, visits, well related compared before treatment. These who never taken those been previously therapies, results show translates into